SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated November 18, 2022, details a material definitive agreement and unregistered sales of equity securities by BioSig Technologies, Inc. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Capital Raise
- Primary Offering: Sold 3,541,469 shares of Common Stock at $0.41 per share for gross proceeds of $1,452,000.
- Warrant Exercises: Received $218,250 from the exercise of 873,000 shares of Common Stock under March 2022 warrants (exercise price reduced to $0.25).
- Total Proceeds: Combined total consideration received from the primary offering and warrant exercises is $1,670,250.
- Debt and Liquidity: The filing does not provide specific data on total debt, cash flow, or liquidity positions beyond the immediate proceeds from these transactions.
Material Changes and Transactions
The primary material change is the entry into a Securities Purchase Agreement with accredited investors under Section 4(a)(2) and Regulation D exemptions. Additionally, the company executed a temporary reduction in the exercise price of previously issued warrants from $1.40 to $0.25 per share, effective through November 10, 2022, which facilitated the issuance of 510,000 shares during that window.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard representations and warranties typical for this transaction type. The transaction was executed to raise capital, but the filing does not specify the intended use of proceeds.
Investor Verification Checklist
- Verify the dilution impact of the 3,541,469 new shares and the 873,000 shares issued via warrant exercise on existing shareholders.
- Confirm the remaining number of unexercised March Warrants and their current exercise price post-November 10, 2022.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions imposed on the company.
- Check subsequent filings for the actual use of the $1,670,250 in proceeds.